Previous studies (1-3) have demonstrated that staphylococcal coagulase is antigenic. During the course of these investigations it was observed that the anticoagulase titer of human sera varied considerably and could not always be correlated with a past history of staphylococcal infections. It seemed possible that staphylococcal coagulases might differ antigenically. The present paper reports observations concerning the antigenic relationships of several cell-free preparations of coagulase.
SPECIFIC COAGULASES Olr STAPHYLOCOCCUS AUREUS

RESULTS
Obserr~ions of Human S~m.--The antibody titer of 148 specimens of serum obtained from medical students was measured with the 3 antigens, each of which had been carefully standardized several times. A group of Titers are expressed as units of anticoagulase in the initial dilution of serum. If the 2 antigens were measuring the same inhibitor, all titers should fall within the diagonal lines which delineate the magnitude of technical error involved in the test.
30 to 40 sera was tested against all antigens each day the test was performed. The results are tabulated in Tables I, II, and III. The anticoagulase titer was less than 11 in 27, 89, and 81 specimens of serum when tested with coagulases I, II, and III, respectively. These data suggest that coagulase I may be unrelated to coagulases II and III. Inspection of Table III indicates that coagulases II and III may not be related since 29 of the 89 sera which had titers of less than 11 when tested with coagulase II, showed titers of 17 or greater when tested with coagulase III.
Certain sera, especially those exhibiting a high anticoagulase titer when tested with preparation I, exhibited a high titer to more than one antigen. This result suggests either that these antigens were related or that individuals whose sera show high anticoagulase titers are also likely to possess antibodies Table I. to other coaguIase preparations. That the antigens are not necessarily related is suggested by the fact that sera showing a high titer to one antigen may contain no detectable antibody to a second antigen. There were 5 specimens with a titer of anticoagulase of 900 when tested with coagulase I (Tables I and I-I) ; one of these showed no antibody against coagulase III, and 2 showed titers of < !l when tested with preparation II. See Table I. sented in Table IV . Forty-four serum specimens were examined using as antigens two separate coagulase lots prepared from strain I. These two lots were prepared at different times and differed in their coagulase activities.
The antibody titers of all sera fell within the 1Lrnits of technical error. Thirty of the 44 were found to have the same anticoagulase titer with the 2 antigens; the remainder of the sera showed only a one dilution variation in titer.
Immunization Experiments.-
Monkeys were inoculated with cell-free coagulase, and the anficeagulase titers to the 3 antigens were determined in one test. The results of one such study are shown in Fig. 1 . This monkey received 3 series of injections of coagulase III during a period of 33 days, a total of The differences in the antibody response to the 3 antigens can be explained by the different amounts of antigens used. This experiment suggests that the 3 antigens are different, but antigens I and II may be related to antigen III, since administration of the former 2 antigens resulted in a slight rise in antibodies when tested with coagulase III. A second monkey was inoculated with 0.5 ml. of an overnight culture of S. aureu~ of coagulase type I and 3.0 ml. of strain 55, ~ the antigenic composition of which was not known (Fig. 2) . Boils did not develop and the only evidence of infection was slight redness and induration appearing 48 hours after the injection. There was no change in the anticoagulase titers following this apparently mild infection. On the 46th day after the inoculation of staphylococci a series of cell-free coagulase injections was instituted, using coagulase II prepared from strain 142 grown in plasma. The total number of units injected could not be measured, hut the preparation clotted fibrinogen after 3 hours' incubation in an initial dilution of 1:55, indicating moderate activity. There was no change in the antibody titers measured with the 3 antigens.
Finally the monkey received 10 injections of 2 ml. each of an overnight culture of organisms
Staphylococcus strain 55 was used in this and subsequent experiments in a study of the immune mechanisms, the results of which will be reported in a subsequent communication.
which produced coagniase I. Boils, which subsequently drained, were produced by each series of injections of S. aureus. There was an immediate increase in anticoagnlase measured with type I antigen, but the anticoaguiase titers to types II and III coagulases did not change. These experiments in this monkey are significant not only because they show a specific response to the homologous coagnlase, but because anticoagnlase developed following an induced infection.
The final immunization experiment to be presented in detail is shown in Fig. 3 . This animal was first inoculated with cell-free coagulase I prepared in broth containing plasma. It was active in an initial dilution of 1:25 as determined by 3 hours' incubation at 37°C. A total of 36 ml. was administered in 18 injections. There was an immediate elevation of anticoagnlase when measured by antigen I, but no increase, other than a slight rise on the 42nd day, to the II and III antigens. On the 73rd day the animal was injected with an overnight culture of S. aureus of coagulase type I and strain 55; 0.5 ml. and 3.0 ml. respectively being administered intramuscularly. These injections resulted in the production of a large boil and an increase in the anticoagnlase titer of the convalescent serum when tested with the type III antigen. The anticoagnlase titer to coagulase I, which had been falling, remained at a constant level for 45 days. It is possible that the rise in the anticoagniase titer against type III antigen may be due to the presence of a similar antigen in strain 55, or it may be related to the infection produced by the organisms of coagulase type I.
Cell-free type II coagulase made in plasma broth was now administered. Ten injections of 3 ml. each were given. The preparation clotted fibrinogen in an initial dilution of 1:55. An immediate increase in titer to coagulase II resulted, as well as an increase of anticoagulase to the III antigen, and to a lesser extent to I antigen.
A total of 240 units of cell-free coagulase type I was given in a second series of injections. 
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Again there was an increase in the homologous antibodies, and a slight increase in antibodies to coagulases II and III. Finally, the animal received 15 more injections of coagulase II, a total of 1,675 additional units. There was a response in the anticoagulase titer of the homologous type, and to a lesser extent in that of type III. The titers of antibody to the 3 antigens then declined at different rates.
Monkeys were injected with 6 preparations of cell-free coagulase derived from different strains of staphylococci. Among these, coagulases I, II, and III appeared to be most distinct antigenically. Few cross-reactions were observed between coagulases I and II, and in each instance they were of minor degree and may represent an anamnestic reaction. In contrast, coagulase II appeared to stimulate antibodies of the III type (Fig. 3) , and in other studies not reported here, the injection of coagulase I was followed by an increase in the titer of antibodies to coagulase III.
The results indicate that coagulases vary antigenically although certain cross-reactions occur. It seems probable, therefore, that the differences noted with human sera tested with coagulase from different strains of staphylococci can be explained on this basis.
Neutralization Experiments
The immunization experiments demonstrated that monkeys responded by antibody formation to the homologous antigen. If the coagulase preparations employed were truly distinct, it should be possible to remove or to neutralize one antibody without affecting appreciably the concentration of the heterologous antibody. Furthermore, possible cross-reactions between the coagulase preparations might become more apparent by employing such techniques.
Three procedures were used in these experiments: The serum was mixed with staphylococcal cells, with collodion particles coated with coagulase, or with cell-free coagulase.
Neutralization with Staphylococcal Cells.-One ml. of an overnight culture of S. aureus producing coagulase II was placed in 50 ml. tryptose broth containing 1 ml. of albumin. Mter incubation for 48 hours at 37°C., the cells were sedimented by centrifugation. The supernatant was decanted and buffer was added to make a 1:5 dilution of the bacterial cells. To 0.5 ml. of the bacterial suspension was added 0.5 ml. of monkey serum. A similar amount of buffer was added in a second tube to 0.5 ml. of the same monkey serum. The 2 tubes were placed at 4°C. overnight during which time they were agitated occasionally. Following centrifugation the supernates were removed. The two serum specimens were then inactivated twice at 60°C. /or 20 minutes and the antibody content determined by the method described (4). The results are shown in Table V. There was only a slight decrease in the antibody to coagulase II, whereas the antibody to coagulase I did not change. No further attempts to neutralize with organisms were made.
Neutralization with Coated Collodion Particles.-
Collodion particles were prepared by the method of Cavelti (5), but no attempt was made to obtain particles of constant size. Preliminary experiments showed that coagulase was removed from broth preparations absorbed with collodion particles overnight. In each experiment particles exposed to coagulase and, as a control, to tryptose broth were used. Mter inactivation at 60°C. for 20 minutes on two occasions, 2 equal portions of the serum were placed in contact with measured quantities of coagulase-coated particles and control particles, respectively, for a period of 1 to 3 hours at 37°C. The particles were then removed by centrifugation and the procedure repeated. The results of 3 neutralization experiments are shown in Table V .
In one instance there was a definite decrease in the antibody titer to coagulase I when the serum was neutralized with collodion particles coated with coagulase I, whereas there was no change in the coagulase II antibody titer. On neutralization with particles coated with coagulase III, there was a decrease in titer of the homologous antibody and no change in the titer of antibodies of the coagulase I type. In the third neutralization, coagulase III particles caused a decrease in both antibodies of the II and III type, with no change in the coagulase I antibodies.
Neutralization with Cell-Free Coagulase.--
The serum to be neutralized with cell-free coagulase was first inactivated in a water bath at 60°C. for 20 minutes. It was then placed at 4°C. for 1 hour and again inactivated at 60°C. for 20 minutes: Following this treatment the serum was divided into 2 equal samples and cell-free coagulase was added to one sample and an equal quantity of broth containing albumin was added to the other. The solutions were mixed and placed at 4°C. overnight. Antibody titrations were performed on each of the 2 specimens.
Since it was necessary to determine whether an excess of coagulase was used in the neutralization experiments, the specimen of serum containing coagulase was also diluted in phosphate buffer in a series of tubes and the substrate, containing fibrinogen, reacting factor, and heparin, was added. Mter the addition of the substrate all solutions were placed in a water bath at 37°C. for 3 hours. The tubes were then examined with a hand lens for evidence of clot formation. If there was clot formation in any dilution of the tubes containing the neutralized serum and the substrate, the experiment was repeated using smaller amounts of coagulase for neutralization.
The results of several such experiments are recorded in Table V . In these experiments it was necessary to perform several preliminary studies so that the proper proportion of serum and coagulase could be determined.
As is evident from the results, neutralization with coagulase I caused a definite and marked decrease in the antibody to coagulase I, whereas the antibody to coagulase II remained constant, or in one instance decreased one dilution increment. In the experiment where the serum was neutralized with coagulase II there was a decrease in antibodies to coagulase II, and a one dilution drop in the antibody to coagulase I. Absorption of serum with coagulase III resulted in a drop of the antibody titer to both coagulases III and I
DISCUSSION
The data presented again confirm the antigenicity of cell-free staphylococcal coagulase. In addition, it was found that in one monkey infected with a culture of S. aureus there was an increase in antibodies to the homologous coagulase preparation. Although it is possible that antibody production in this animal was due to preformed coagulase present in the culture medium, the amount should have been small since maximum production requires several days of incubation. Subsequent studies have demonstrated the production of anticoagulase following induced infections with washed staphylococcal cells (6) .
These results show that there are at least 2 separate coagulases produced by different strains of S. aureus and explain, in part, the difficulties encountered in the past in the immunological study of plasma or serum of patients with staphylococcal infections.
Sudhues and Schimrigk (7) found that plasma of normal subjects and patients with staphylococcal infections showed no differences in susceptibility to staphylocoagulase. Likewise Cruickshank (8) found that the plasmas of 4 patients with staphylococcal infections were normally susceptible to clotting with coagulase. Tager (9) has studied the resistance of human plasma to cell-free coagulase and has found a large proportion to be resistant. No attempt was made to correlate these findings with a previous history of a staphylococcal infection.
Lominski and Roberts (10) tested 348 sera, of which 212 contained an inhibitory substance to coagulase. They found that the incidence of low titer or non-inhibitory sera was higher in the patients with major staphylococcal infections than in healthy subjects or patients with diseases not caused by staphylococci. They suggest that a low titer predisposes to staphylococcal infections. This suggestion is difficult to understand in view of the observation made by the same authors that the inhibitory substance may be an antibody. Their results are best explained by the failure to use the proper coagulase preparation so that antibody to the specific coagulase could be identified. Using such techniques in this laboratory, it has been possible to show that individuals with staphylococcal infections do exhibit an inhibitory substance in their convalescent sera. Another factor which may have influenced the results obtained by Lominski and Roberts (10) is that the technique employed for measuring the inhibitory substance in sera did not control the amount of reacting substance. Since clotting results from an interaction of coagulase and the reacting factor, it is necessary to control both factors when measuring anticoagulase.
The data presented would appear to establish more firmly that the inhibitor of coagulase is an antibody. The differences in the titer of coagulase inhibitors in human serum depending on the type of coagulase used indicate that the inhibitor in this instance is specific. Furthermore, the neutralization experiments with human and monkey serum which demonstrated the specificity of the reaction, would support the thesis that the inhibitor is antibody.
Although the name, coagulase, implies that the substance is an active clotting enz)nue, there is little evidence to support such a thesis. It is known that staphylococcal coagtflase requires a second factor found in blood of certain species for the production of the active clotting substance. Smith and Hale (11) termed this blood factor, activator. However, as Kaplan and Spink (12) emphasize, coagulase may be the activator. For this reason the term "reacting factor" is employed, as first suggested by Tager (13) . Until the mechanism of the reaction is further clarified it would appear that antigenically different coagulases have similar properties so far as reacting with a substance in blood to produce an active clotting substance.
The demonstration of serological differences in the coagulases suggests that strains of S. aureus might be differentiated by this means. At the present time the number of staphylococcal coagulases is not known, but it would appear that cross-reactions may preclude the use of coagulases as a means to differentiate more than a few strains. Thus, coagulase III appears to be related in part to both coagulases I and II. Preliminary observations employing other coagulase preparations indicate that such cross-reactions may be common. It is possible also that mutations occur, so that the coagulase type changes.
SLrMMARY
Three staphylococcal coagulases termed I, II, and III were differentiated by measuring the antibody titer of human sera. Coagulases I and II are antigenically distinct; coagulase III appears to be related to both coagulases I and II. These results were confirmed by specific neutralization experiments.
These observations emphasize the importance of employing the correct type of coagulase in studying the role of this substance in the pathogenesis of staphylococcal infections. Preliminary observations in animals indicate that specific anticoagulase develops following induced infections. The role of this antibody in the recovery mechanism remains to be determined.
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